Chardan Capital Initiates Avalanche Biotechnologies With Neutral

Monica Gerson , Benzinga Staff Writer

February 19, 2015 9:04am Comments

Analysts at Chardan Capital initiated coverage on Avalanche Biotechnologies, Inc. (NASDAQ: AAVL) with a Neutral rating.

The target price for Avalanche Biotechnologies is set to $40.

Avalanche Biotechnologies' shares rose 7.90% to close at $39.74 yesterday.

Date	Firm	Action	From	To
Mar 2016	Chardan Capital	Maintains		Buy
Feb 2016	Jefferies	Maintains		Buy
Jun 2015	Chardan Capital	Upgrades	Sell	Neutral

Posted-In: Chardan Capital Initiation Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
SEDG	B of A Securities	Maintains	411.0
PTLO	Piper Sandler	Maintains	28.0
AOUT	Lake Street	Maintains	26.0
RAPT	Piper Sandler	Maintains	52.0
OCX	Lake Street	Maintains	6.0

1	LLY: Eli Lilly Co. Q2 FY2025 Earnings Transcript
2	COP, UBER: Nasdaq Surges Over 1% Amid Jump In Apple Shares: Fear & Greed In...
3	CART, MCK: Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: Wh...
4	REFR, ECVT: Earnings Scheduled For August 7, 2025
5	CVNA, AMZN: Carvana CEO Ernest Garcia, VP General C...
6	TMUS: Here's How Much $1000 Invested...
7	NVO, LLY: Eli Lilly's Closely Wa...

1	'The Best Houses Are The Ones That Are Really Dated' — Graham Stepha...
2	STRL: Here's How Much $100 Invested In Sterling Infrastructure 15 Years Ago W...
3	CMG: $100 Invested In Chipotle Mexican Grill 15 Years Ago Would Be Worth This...
4	COOP: $100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
5	GE: Here's How Much You Would Have Made Owning GE Aerospace Stock...
6	PH: $100 Invested In This Stock 20 Years Ago Would Be Worth This Much...
7	LNW: Assessing Light & Wonder: Insights From 6 Financial Analysts

Market Overview